» Articles » PMID: 12773040

Design, Synthesis, and Structure-activity Relationships of Alkylcarbamic Acid Aryl Esters, a New Class of Fatty Acid Amide Hydrolase Inhibitors

Overview
Journal J Med Chem
Specialty Chemistry
Date 2003 May 30
PMID 12773040
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Fatty acid amide hydrolase (FAAH), an intracellular serine hydrolase enzyme, participates in the deactivation of fatty acid ethanolamides such as the endogenous cannabinoid anandamide, the intestinal satiety factor oleoylethanolamide, and the peripheral analgesic and anti-inflammatory factor palmitoylethanolamide. In the present study, we report on the design, synthesis, and structure-activity relationships (SAR) of a novel class of potent, selective, and systemically active inhibitors of FAAH activity, which we have recently shown to exert potent anxiolytic-like effects in rats. These compounds are characterized by a carbamic template substituted with alkyl or aryl groups at their O- and N-termini. Most compounds inhibit FAAH, but not several other serine hydrolases, with potencies that depend on the size and shape of the substituents. Initial SAR investigations suggested that the requirements for optimal potency are a lipophilic N-alkyl substituent (such as n-butyl or cyclohexyl) and a bent O-aryl substituent. Furthermore, the carbamic group is essential for activity. A 3D-QSAR analysis on the alkylcarbamic acid aryl esters showed that the size and shape of the O-aryl moiety are correlated with FAAH inhibitory potency. A CoMSIA model was constructed, indicating that whereas the steric occupation of an area corresponding to the meta position of an O-phenyl ring improves potency, a region of low steric tolerance on the enzyme active site exists corresponding to the para position of the same ring. The bent shape of the O-aryl moieties that best fit the enzyme surface closely resembles the folded conformations observed in the complexes of unsaturated fatty acids with different proteins. URB524 (N-cyclohexylcarbamic acid biphenyl-3-yl ester, 9g) is the most potent compound of the series (IC(50) = 63 nM) and was therefore selected for further optimization.

Citing Articles

Activity of FAAH-Inhibitor JZP327A in an Experimental Rat Model of Migraine.

Greco R, Francavilla M, Demartini C, Zanaboni A, Facchetti S, Palmisani M Int J Mol Sci. 2023; 24(12).

PMID: 37373250 PMC: 10299064. DOI: 10.3390/ijms241210102.


Characterization of URB Series Synthetic Cannabinoids by HRMS and UHPLC-MS/MS.

Agostini M, Favretto D, Renzoni C, Vogliardi S, Duranti A Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259350 PMC: 9966132. DOI: 10.3390/ph16020201.


Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.

Maccarrone M, Di Marzo V, Gertsch J, Grether U, Howlett A, Hua T Pharmacol Rev. 2023; 75(5):885-958.

PMID: 37164640 PMC: 10441647. DOI: 10.1124/pharmrev.122.000600.


The Endocannabinoid System as a Target for Neuroprotection/Neuroregeneration in Perinatal Hypoxic-Ischemic Brain Injury.

Duranti A, Beldarrain G, Alvarez A, Sbriscia M, Carloni S, Balduini W Biomedicines. 2023; 11(1).

PMID: 36672536 PMC: 9855621. DOI: 10.3390/biomedicines11010028.


Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine.

Greco R, Demartini C, Zanaboni A, Francavilla M, Reggiani A, Realini N J Headache Pain. 2022; 23(1):79.

PMID: 35799128 PMC: 9264488. DOI: 10.1186/s10194-022-01449-1.